Biocon Bids On Global GLP-1 Opportunities To Grow Generics Division As Q3 Sales Decline
Indian Firm’s Generic Semaglutide Unlikely To Be Amongst First Market Entrants
Biocon reported another quarter of sluggish generics revenues but hopes that planned generic liraglutide launches and US facility expansion will grow this business segment.
